The collective results may explain the difference between the models toward sunitinib treatment: in NU12 tumors vascularization is mainly driven by VEGFA/B but also by PGF and the tumor vasculature highly expresses sunitinib's main targets VEGFR1,2,3 facilitating destruction of endothelial cells by sunitinib. The gene discussed is FLT1; the disease is neoplasm.